InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-53.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
No signal scores available.
Discover the detailed record of transactions filed by Haft Nicholas, Director. Director active across 1 company, notably Finch Therapeutics Group, Inc.. Cumulatively, 1 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €578k. Activity tracked since 20 December 2021. The latest transaction was disclosed on 20 December 2021 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Haft Nicholas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations1 total
63,850 shares@ US$10.18100.0% of flowCommon Stock, $0.001 par value per shareSEC:0001567619-21-022453:0
Canonical exit: 20 Mar 2022 (T+90)
1 of 1 declaration
About Haft Nicholas
Nicholas Haft is a Director at Finch Therapeutics Group, Inc. In this role, he participates in the governance of the company and strategic decision-making. His expertise in biotechnology is valuable for Finch Therapeutics, which develops innovative therapies.
